With covalent meds abuzz, RA Capital and Novartis lead $56M seed round for new startup
Seeing the successes of other covalent medicines companies, a group of blue-chip investors is lining up to take the next shot on goal.
RA Capital …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
